Objective To evaluate the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (AIIRAs) on renal outcomes and all cause mortality in patients with diabetic nephropathy. Data sources Medline, Embase, the Cochrane controlled trials register, conference proceedings, and contact with investigators. Study selection Trials comparing ACE inhibitors or AIIRAs with placebo or with each other in patients with diabetic nephropathy. Data extraction Mortality, renal outcomes (end stage renal disease, doubling of serum creatinine concentration, prevention of progression of microalbuminuria to macroalbuminuria, remission of microalbuminuria), and quality of trials. Data synthesis 36 of 43 identified trials compared ACE inhibitors with placebo (4008 patients), four compared AIIRAs with placebo (3331 patients), and three compared ACE inhibitors with AIIRAs (206 patients). We obtained unpublished data for 11 trials. ACE inhibitors significantly reduced all cause mortality (relative risk 0.79, 95% confidence interval 0.63 to 0.99) compared with placebo but AIIRAs did not (0.99, 0.85 to 1.17), although baseline mortality was similar in the trials. Both agents had similar effects on renal outcomes. Reliable estimates of the unconfounded relative effects of ACE inhibitors compared with AIIRAs could not be obtained owing to small sample sizes. Conclusion Although the survival benefits of ACE inhibitors for patients with diabetic nephropathy are known, the relative effects of ACE inhibitors and AIIRAs on survival are unknown owing to the lack of adequate head to head trials.
BackgroundAngiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally e ective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered.
ObjectivesTo evaluate the benefits and harms ACEi and AIIRA in patients with DKD.
There are an estimated 14,000 randomized trials published in chronic
kidney disease. The most frequently reported outcomes are biochemical endpoints,
rather than clinical and patient-reported outcomes including cardiovascular
disease, mortality, and quality of life. While many trials have focused on
optimizing kidney health, the heterogeneity and uncertain relevance of outcomes
reported across trials may limit their policy and practice impact. The
international Standardized Outcomes in Nephrology (SONG) Initiative was formed
to identify core outcomes that are critically important to patients and health
professionals, to be reported consistently across trials. We convened a SONG
Implementation Workshop to discuss the implementation of core outcomes.
Eighty-two patients/caregivers and health professionals participated in plenary
and breakout discussions. In this report, we summarize the findings of the
workshop in two main themes: socializing the concept of core outcomes, and
demonstrating feasibility and usability. We outline implementation strategies
and pathways to be established through partnership with stakeholders, which may
bolster acceptance and reporting of core outcomes in trials, and encourage their
use by end-users such as guideline producers and policymakers to help improve
patient-important outcomes.
Treatment of children with vesicoureteric reflux has not been accompanied by the hoped-for reduction in the incidence of ESRD attributable to reflux nephropathy. A randomized trial with a control (no-treatment) arm is required to appropriately assess the medical belief that long-term antibiotics and surgery improve the natural history of vesicoureteric reflux.
This updated review increases the body of evidence that oral antibiotics alone are as effective as a short course (three to four days) of IV antibiotics followed by oral therapy for a total treatment duration of 10 to 14 days for the treatment of acute pyelonephritis in children. When IV antibiotics are given, a short course (two to four days) of IV therapy followed by oral therapy is as effective as a longer course (seven to 10 days) of IV therapy. If IV therapy with aminoglycosides is chosen, single daily dosing is safe and effective. Insufficient data are available to extrapolate these findings to children aged less than one month of age or to children with dilating vesicoureteric reflux (grades III-V). Further studies are required to determine the optimal total duration of antibiotic therapy required for acute pyelonephritis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.